In Brief: Genentech IGF-1
Executive Summary
Genentech IGF-1: Development of IGF-1 for Type 1 and Type 2 diabetes mellitus to be discontinued following Phase II trials because of the time and expense required to address concerns about the effect of the growth factor on diabetic retinopathy, the company explains. Through Phase II, no IGF-1 trials showed evidence of generalized angiogenic effects on the eyes, Genentech maintains...